| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Oruka Therapeutics, Inc. (ORKA) has 8 insiders with recent SEC Form 4 filings, including 0 buys and 10 sells. ORKA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.13M | $72.72M | - | |
| COO | 206.2K | $13.25M | - | |
| Other | 36.1K | $2.32M | -7,000 | |
| Dir | 35.0K | $2.25M | - | |
| Dir | 17.5K | $1.12M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 18, 2016 | Keuer Thomas A | Chief Operating Officer | Sell | 483 | $2.45 | $1,183.83 | -3.1% | |
| Sep 20, 2016 | Bristow Michael R | Pres. &Chief Executive Offic | Sell | 1,972 | $2.89 | $5,699.08 | -4.4% | |
| Sep 20, 2016 | Keuer Thomas A | Chief Operating Officer | Sell | 714 | $2.89 | $2,063.46 | -4.4% | |
| Sep 20, 2016 | Ozeroff Christopher David | S.v.p., General Counsel | Sell | 1,185 | $2.89 | $3,424.65 | -6.1% | |
| Sep 19, 2016 | Selby Brian L. | VP, Finance | Sell | 476 | $2.91 | $1,385.16 | -15.7% | |
| Apr 5, 2016 | Bristow Michael R | See Remarks | Sell | 724 | $3.52 | $2,548.48 | -1.6% | |
| Apr 5, 2016 | Ozeroff Christopher David | S.v.p., General Counsel | Sell | 366 | $3.52 | $1,288.32 | -1.8% | |
| Apr 5, 2016 | Keuer Thomas A | Chief Operating Officer | Sell | 384 | $3.52 | $1,351.68 | -2.3% | |
| Apr 4, 2016 | Selby Brian L. | VP, Finance | Sell | 1,114 | $3.52 | $3,921.28 | -26.9% | |
| Mar 1, 2016 | Keuer Thomas A | Chief Operating Officer | Sell | 457 | $3.53 | $1,613.21 | -2.7% |